VNRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
VolitionRX Ltd (VNRX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock exhibits weak technical indicators, negative sentiment from analysts, and lacks strong positive catalysts to justify a buy decision. Additionally, the company's financials, while showing revenue growth, still reflect significant losses and declining EPS. The absence of strong trading signals further supports a hold recommendation.
The technical indicators for VNRX are bearish. The MACD is negative and expanding downward, the RSI is neutral at 22.646, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.146, with resistance levels at 0.162 and 0.178. Overall, the trend suggests further downside potential in the short term.
Approval from NYSE American for compliance plan to maintain listing.
Launch of the rNuQ webshop to expand product offerings in disease research and drug development.
Recent 1-for-20 reverse stock split, signaling potential financial stress and listing pressure.
Analysts have downgraded the stock and lowered price targets.
Weak technical indicators and bearish stock trend.
In Q4 2025, revenue increased by 133.25% YoY to $447,034, but net income remained negative at -$6,270,832, improving only 8.24% YoY. EPS dropped by -16.67% YoY to -0.05. Gross margin remained flat at 100%. While revenue growth is notable, the company is still operating at a significant loss.
Analysts have a negative outlook on VNRX. D. Boral Capital downgraded the stock to Hold from Buy, citing the reverse stock split as a sign of financial stress. H.C. Wainwright lowered the price target from $1.50 to $1.00, maintaining a Buy rating but citing an increased share count as the reason for the adjustment.
